<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336800">
  <stage>Registered</stage>
  <submitdate>12/04/2011</submitdate>
  <approvaldate>13/04/2011</approvaldate>
  <actrnumber>ACTRN12611000381987</actrnumber>
  <trial_identification>
    <studytitle>Re-evaluation of Midazolams Objective Value by Exclusion</studytitle>
    <scientifictitle>In intubated patients in the intensive care unit, does introducing a unit protocol that restricts the use of midazolam as a sedative used by continuous infusion to a limited set of indications reduce the use of antipsychotic medications and other delirium-sensitive outcomes, in comparison to standard practice in equivalent historical periods.</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>REMOVE</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Delirium associated with critical illness</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A clinical guideline for intubated patients in the ICU that restricts continuous IV midazolam use to patients with one of a select list of indications: seizures, alcohol withdrawal, requirement for dangerously high doses of other sedatives. The rate of midazolam infusion under these circumstances will be determined by the physician responsible for the patient's ICU management, using standard clinical assessments to measure response, for the duration judged clincially appropriate.</interventions>
    <comparator>Historical controls from a period 3 months immediately prior to the introduction of the guideline, and in the equivalent 3 month period in the preceeding year.</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Antipsychotic use (i.e. total use of quetiapine, haloperidol, olanzapine, dexmedetomidine and clonidine, the agents listed in the ICU delirium protocol)</outcome>
      <timepoint>cumulative use (total quantity, number of doses, mean and median dose) over the entire ICU admisison</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>hours intubated</outcome>
      <timepoint>entire ICU admisison</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ICU length of stay</outcome>
      <timepoint>end of ICU admisison</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospital length of stay</outcome>
      <timepoint>end of Hospital admission</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of mechanical restraint while intubated</outcome>
      <timepoint>end of ICU admission</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ICU mortality</outcome>
      <timepoint>end of ICU admission</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospital mortality</outcome>
      <timepoint>end of Hospital admission</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of alternative sedative agents</outcome>
      <timepoint>end of ICU admission</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All mechanically ventilated patients admitted to the ICU in the study period</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>None</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>All mechanically ventilated patients admitted to the ICU during the study period will be treated using the new, evidence-based guideline.</concealment>
    <sequence>NA</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Before and after design.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Hospital</primarysponsorname>
    <primarysponsoraddress>Intensive Care Unit
Studley Road
Heidelberg VIC 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Hospital</fundingname>
      <fundingaddress>Intensive Care Unit
Studley Road
Heidelberg VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is abundant observational evidence that midazolam, a benzodiazepine drug used for
sedation, use is associated with delirium in ICU patients. However, despite the availability of an
equally effective alternative, benzodiazepines usage remains high. The most likely explanation
for is that clinicians are not sufficiently convinced by the quality of the observational studies.
This is a reasonable criticism, as it is unlikely that it was possible to adjust for all sources of
indication bias in these studies. We hypothesise that introducing a clinical guideline for
intubated patients in the Austin Hospital ICU that restricts midazolam use to patients with one
of a select list of indications will a. reduce the use of midazolam and b. reduce the incidence of
surrogate markers of delirium in ICU patients, without c. significantly increasing cost of
sedative medications in the ICU.</summary>
    <trialwebsite>NA</trialwebsite>
    <publication>NA</publication>
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Hospital</ethicname>
      <ethicaddress>Studley Road
Heidelberg VIC 3084</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>12/04/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Michael Reade</name>
      <address>Austin Hospital ICU
Studley Rd, Heidelberg VIC 3084</address>
      <phone>+61394965000</phone>
      <fax>+61394963932</fax>
      <email>mreade@doctors.net.uk</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Michael Reade</name>
      <address>Austin Hospital ICU
Studley Rd, Heidelberg VIC 3084</address>
      <phone>+61394965000</phone>
      <fax>+61394963932</fax>
      <email>mreade@doctors.net.uk</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Michael Reade</name>
      <address>Austin Hospital ICU
Studley Rd, Heidelberg VIC 3084</address>
      <phone>+61394965000</phone>
      <fax>+61394963932</fax>
      <email>mreade@doctors.net.uk</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>